Sampre Nutritions Ltd
Sampre Nutritions Ltd (SAMPRE) last reported results for the quarter ended Jun 2026, with sales of ₹14.85 crore and net profit of ₹0.7 crore. The stock last traded at ₹6.1, a market capitalisation of ₹58 crore, on a P/E of 16.2. Over the past 52 weeks the stock has ranged between ₹4.51 and ₹42.3. Figures are as of 6 Oct 2026 and are not real time.
Sampre Nutritions Ltd share price and key metrics
- Current price
- ₹6.1
- Market cap
- ₹58 cr
- Stock P/E
- 16.2
- Book value
- ₹11.3
- ROE
- 3.11%
- ROCE
- 2.71%
- Dividend yield
- 0.00%
- 52w high / low
- 42.3/4.51
Metrics as of 6 Oct 2026. Not real time.
Track Sampre Nutritions Ltd
Cruxal reads every Sampre Nutritions Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sampre Nutritions Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 5%
- TTM
- 50%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 106%
- TTM
- 151%
- 10 Years
- -7%
- 5 Years
- 7%
- 3 Years
- -20%
- 1 Year
- -81%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -2%
- Last Year
- 3%
Sampre Nutritions Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹14.85 cr, up 36.6% from ₹10.87 cr a year earlier. Net profit was ₹0.7 cr, down 1.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7.27 | 5.58 | 7.77 | 10.87 | 10 | 7.39 | 15.1 | 14.85 |
| Expenses | 6.26 | 5.14 | 14.04 | 9.49 | 8.06 | 5.91 | 14.67 | 13.35 |
| Operating profit | 1.01 | 0.44 | -6.27 | 1.38 | 1.94 | 1.48 | 0.43 | 1.5 |
| OPM % | 13.89% | 7.89% | -80.69% | 12.70% | 19.40% | 20.03% | 2.85% | 10.10% |
| Other income | 0 | 0.04 | 0.31 | 0.03 | 0.01 | 0 | 0.67 | 0.07 |
| Interest | 0.45 | 0.59 | 0.58 | 0.31 | 0.28 | 0.26 | 0.51 | 0.26 |
| Depreciation | 0.44 | 0.44 | 0.66 | 0.39 | 0.61 | 0.5 | 0.54 | 0.51 |
| Profit before tax | 0.12 | -0.55 | -7.2 | 0.71 | 1.06 | 0.72 | 0.05 | 0.8 |
| Tax % | 0.00% | 0.00% | 2.08% | 0.00% | 16.04% | 13.89% | -2,600.00% | 12.50% |
| Net profit | 0.12 | -0.54 | -7.35 | 0.71 | 0.9 | 0.62 | 1.35 | 0.7 |
| EPS (₹) | 0.03 | -0.08 | -0.88 | 0.08 | 0.10 | 0.07 | 0.14 | 0.07 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sampre Nutritions Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 37.11 | 25.15 | 25.12 | 43.35 | 47.34 |
| Operating profit | 4.06 | 4.12 | -3.85 | 4.78 | 5.35 |
| OPM % | 10.94% | 16.38% | -15.33% | 11.03% | 11.30% |
| Net profit | 0.35 | 0.23 | -7.67 | 3.08 | 3.57 |
| EPS (₹) | 0.13 | 0.08 | -0.91 | 0.32 | 0.38 |
TTM is the trailing twelve months to the most recent quarter.
Sampre Nutritions Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 6.87 | 7.27 | 21.01 | 47.50 |
| Reserves | 14.29 | 15.20 | 69.87 | 59.85 |
| Borrowings | 16.77 | 17.50 | 16.90 | 17.91 |
| Other liabilities | 5.66 | 4.78 | 7.65 | 9.12 |
| Total liabilities | 43.59 | 44.75 | 115.43 | 134.38 |
| Fixed assets | 20.52 | 21.06 | 19.86 | 20.10 |
| CWIP | 4.16 | 5.50 | 5.01 | 5.01 |
| Investments | 0.01 | 0.01 | 73.51 | 83.47 |
| Other assets | 18.90 | 18.18 | 17.05 | 25.80 |
| Total assets | 43.59 | 44.75 | 115.43 | 134.38 |
As reported by the company. Total assets equal total liabilities by construction.
Sampre Nutritions Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 0.88 | 3.95 | 0.08 | -1.10 |
| Cash from investing | -4.32 | -3.70 | -75.17 | -2.75 |
| Cash from financing | 3.48 | -0.09 | 75.03 | 3.70 |
| Net cash flow | 0.04 | 0.16 | -0.05 | -0.15 |
| Free cash flow | -3.44 | 0.24 | -0.20 | -3.39 |
| CFO / operating profit | 28% | 91% | -5% | -23% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sampre Nutritions Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 6.19% | -7.38% | 2.71% |
| Debtor days | 73.47 | 97.53 | 128.59 | 111.82 |
| Inventory days | 168.94 | 552.24 | 249.30 | 186.05 |
| Days payable | 92.15 | 150.08 | 199.09 | 134.64 |
| Cash conversion cycle | 150.26 | 499.68 | 178.80 | 163.22 |
| Working capital days | 49.37 | 50.36 | 29.35 | 71.65 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sampre Nutritions Ltd shareholding pattern
Promoters held 14.04% at Jun 2026, up from 12.11% at Jun 2025. FIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 28.36% | 14.16% | 14.16% | 12.11% | 12.11% | 15.26% | 14.04% | 14.04% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.43% | 0.00% |
| Public | 71.63% | 85.83% | 85.85% | 87.89% | 87.89% | 84.75% | 85.54% | 85.96% |
| No. of shareholders | 4,586 | 5,346 | 5,359 | 5,301 | 6,538 | 8,890 | 8,560 | 8,947 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sampre Nutritions Ltd corporate filings
- Closure of Trading Window for the Second Quarter ended 30 September 2026.Insider Trading / SASTlow impact
- Sampre Nutritions Limited approves preferential allotment of 17.71 lakh equity shares to promoters via debt-to-equity conversionOthersmedium impact
Cruxal's analysis: Sampre Nutritions Limited has completed the conversion of unsecured loans into equity…
Read the full analysis - Sampre Nutritions Limited Announces Successful Conclusion of 35th AGM and Approval of Director Remuneration RevisionAGM/EGMlow impact
Cruxal's analysis: Sampre Nutritions Limited has successfully concluded its 35th Annual General Meeting held…
Read the full analysis - Sampre Nutritions Limited concludes 35th Annual General Meeting; approves director reappointment and remuneration revisionAGM/EGMlow impact
Cruxal's analysis: Sampre Nutritions Limited has successfully concluded its 35th Annual General Meeting held…
Read the full analysis - Sampre Nutritions Limited Receives BSE In-Principle Approval for Preferential Issue of 17.71 Lakh Equity Shares to PromotersCompany Updatemedium impact
Cruxal's analysis: Sampre Nutritions Limited has received in-principle approval from the BSE to issue 17.71…
Read the full analysis - Sampre Nutritions Limited schedules 35th Annual General Meeting for 04 September 2026AGM/EGMlow impact
Cruxal's analysis: Sampre Nutritions Limited has issued a formal notice regarding its 35th Annual General…
Read the full analysis - Sampre Nutritions Limited Announces 35th AGM and Proposes Significant Remuneration Revision for Whole-Time DirectorAGM/EGMmedium impact
Cruxal's analysis: Sampre Nutritions Limited has scheduled its 35th Annual General Meeting for 04 September…
Read the full analysis - Sampre Nutritions Limited Announces 35th Annual General Meeting for September 2026Company Updatelow impact
Cruxal's analysis: Sampre Nutritions Limited has issued an intimation regarding the publication of its 35th…
Read the full analysis - Sampre Nutritions Limited Announces 35th AGM and Proposes Significant Remuneration Revision for Whole-Time DirectorOthersmedium impact
Cruxal's analysis: Sampre Nutritions Limited has scheduled its 35th Annual General Meeting for 04 September…
Read the full analysis - Sampre Nutritions Limited Announces 35th AGM and Proposes Significant Remuneration Hike for Whole-Time DirectorAGM/EGMmedium impact
Cruxal's analysis: Sampre Nutritions Limited has issued a notice for its 35th Annual General Meeting…
Read the full analysis - Sampre Nutritions Limited Reports Q1 FY27 Financial ResultsCompany Updatelow impact
Cruxal's analysis: Sampre Nutritions Limited has released its unaudited standalone and consolidated…
Read the full analysis - Sampre Nutritions Limited Reports Q1 FY27 Financial Results and Announces Significant Remuneration Hike for Whole-Time DirectorBoard Meetingmedium impact
Cruxal's analysis: Sampre Nutritions Limited reported Q1 FY27 standalone revenue from operations of 14.85…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.